Trial Profile
Ipilimumab in pretreated metastatic malignant melanoma: South African Expanded Access Program (EAP)
Status:
Completed
Phase of Trial:
Clinical Phase Unknown
Latest Information Update: 13 Oct 2017
Price :
$35
*
At a glance
- Drugs Ipilimumab (Primary)
- Indications Malignant melanoma
- Focus Expanded access; Therapeutic Use
- 12 Sep 2017 Results of five-year long-term follow-up data (as of Sep 2016) presented at the 42nd European Society for Medical Oncology Congress
- 21 Jul 2015 New trial record
- 02 Jun 2015 Results presented at the 51st Annual Meeting of the American Society of Clinical Oncology.